An additional peril of pathologic complete response.

Area of Science:

• Oncology
• Radiotherapy
• Breast Cancer Research

Background:

• Pathological complete response (pCR) is a significant predictor of long-term outcomes in patients with aggressive early breast cancer receiving neoadjuvant systemic therapy.
• Accurate assessment of pCR is crucial for treatment evaluation and patient management.

Purpose of the Study:

• To critically evaluate the methodologies and challenges associated with determining pathological complete response (pCR) in breast cancer.
• To identify the essential data required for tailoring radiation therapy strategies in breast cancer patients who achieve pCR.

Main Methods:

• Review of current literature on pCR assessment in breast cancer.
• Analysis of clinical trial data and guidelines related to neoadjuvant therapy and radiation oncology.
• Discussion of the implications of pCR on treatment de-escalation and intensification.

Main Results:

• Variability exists in the definition and pathological assessment of pCR across different studies and institutions.
• Current data are insufficient to definitively guide radiation therapy decisions post-pCR in all patient subgroups.
• The achievement of pCR may warrant de-escalation of radiation therapy in certain contexts, but requires further investigation.

Conclusions:

• Standardization of pCR assessment is needed to improve comparability and reliability of research findings.
• Further research is required to establish robust criteria for tailoring breast cancer radiation therapy after achieving pCR.
• Personalized treatment strategies incorporating pCR status are essential for optimizing outcomes in early breast cancer.